Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: A systematic literature review

Pediatric Rheumatology

Volumn 12, Issue 1, 2014, Pages

  Van Dijkhuizen, Pieter ^a,b   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Adverse events; Efficaciousness; EFficacy; Juvenile idiopathic arthritis; Methotrexate; MTX intolerance; Prediction

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; GAMMA GLUTAMYL HYDROLASE; METHOTREXATE; ABC TRANSPORTER; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; POLYGLUTAMIC ACID;

ARTICLE; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; GASTROINTESTINAL SYMPTOM; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; MEDLINE; MULTIGENE FAMILY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; THROMBOCYTE; ADOLESCENT; ARTHRITIS, JUVENILE; BLOOD; CHILD; GENETICS; PREDICTIVE VALUE; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, ANTINUCLEAR; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; ATP-BINDING CASSETTE TRANSPORTERS; BIOMARKERS; CHILD; CHILD, PRESCHOOL; HUMANS; METHOTREXATE; POLYGLUTAMIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84924091945     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-12-51     Document Type: Article

References (41)

1. Prakken B, Albani S, Martini A: Juvenile idiopathic arthritis. Lancet 2011, 377:2138-2149. 10.1016/S0140-6736(11)60244-4
2. Boers M: Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003, 48:1771-1774. 10.1002/art.11156
3. Tynjala P, Vahasalo P, Tarkiainen M, Kroger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P: Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 2011, 70:1605-1612. 10.1136/ard.2010.143347
4. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, Sundel RP, Milojevic D, Punaro MG, Chira P, Gottlieb BS, Higgins GC, Ilowite NT, Kimura Y, Hamilton S, Johnson A, Huang B, Lovell DJ: Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012, 64:2012-2021. 10.1002/art.34343
5. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, Stanevicha V, Mihaylova D, Ferriani V, Tsakalidou FK, Foeldvari I, Cuttica R, Gonzalez B, Ravelli A, Khubchandani R, Oliveira S, Armbrust W, Garay S, Vojinovic J, Norambuena X, Gamir ML, Garcia-Consuegra J, Lepore L, Susic G, Corona F, Dolezalova P, Pistorio A, Martini A, Ruperto N, Roth J: Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010, 303:1266-1273.
6. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004, 50:2191-2201. 10.1002/art.20288
7. Van Dijkhuizen EHP, Wulffraat NM: Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Annals Rheumatic 2014, 24:6.
8. Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, Malleson PN, Cabral DA: Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004, 31:2501-2506.
9. Bulatovic M, Heijstek MW, Verkaaik M, Van Dijkhuizen EHP, Armbrust W, Hoppenreijs EP, Kamphuis S, Kuis W, Egberts TC, Sinnema G, Rademaker CM, Wulffraat NM: High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 2011, 63:2007-2013. 10.1002/art.30367
10. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G: Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken) 2012, 64:1349-1356. 10.1002/acr.21697
11. Murray KJ, Lovell DJ: Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002, 16:361-378. 10.1016/S1521-6942(02)90234-2
12. van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G: Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 2007, 25:480-485.
13. Brunner HI, Johnson AL, Barron AC, Passo MH, Griffin TA, Graham TB, Lovell DJ: Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol 2005, 11:194-204. 10.1097/01.rhu.0000173616.81928.44
14. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N: 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011, 63:465-482. 10.1002/acr.20460
15. Horneff G: Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 2013, 13:361-376. 10.1517/14712598.2013.735657
16. Bulatovic M, Heijstek MW, Van Dijkhuizen EHP, Wulffraat NM, Pluijm SM, de Jonge R: Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis 2012, 71:1484-1489. 10.1136/annrheumdis-2011-200942
17. de Rotte MC, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RH, Wulffraat NM, de Jonge R: ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol 2012, 39:2032-2040. 10.3899/jrheum.111593
18. Bulatovic Calasan M, den Boer E, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM: Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis 2013. doi:10.1136/annrheumdis-2013-203723
19. Moncrieffe H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, Roth J, Wedderburn LR: A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford) 2013, 52:1467-1476. 10.1093/rheumatology/ket152
20. Tukova J, Chladek J, Hroch M, Nemcova D, Hoza J, Dolezalova P: 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J Rheumatol 2010, 37:2180-2186. 10.3899/jrheum.091427
21. Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A: The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999, 135:316-320. 10.1016/S0022-3476(99)70127-7
22. Cobb J, Cule E, Moncrieffe H, Hinks A, Ursu S, Patrick F, Kassoumeri L, Flynn E, Bulatovic M, Wulffraat N, van Zelst B, de Jonge R, Bohm M, Dolezalova P, Hirani S, Newman S, Whitworth P, Southwood TR, De Iorio M, Wedderburn LR, Thomson W: Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. Pharmacogenomics J 2014, 14:356-364. 10.1038/tpj.2014.3
23. Hinks A, Moncrieffe H, Martin P, Ursu S, Lal S, Kassoumeri L, Weiler T, Glass DN, Thompson SD, Wedderburn LR, Thomson W: Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis 2011, 70:1395-1400. 10.1136/ard.2010.146191
24. Moncrieffe H, Hinks A, Ursu S, Kassoumeri L, Etheridge A, Hubank M, Martin P, Weiler T, Glass DN, Thompson SD, Wedderburn LR: Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenet Genomics 2010, 20:665-676. 10.1097/FPC.0b013e32833f2cd0
25. Bartoli M, Taro M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, Magnani A, Gasparini C, Martini A, Ravelli A: The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:370-374.
26. Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F: Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis. J Rheumatol 2009, 36:2308-2313. 10.3899/jrheum.081156
27. Cespedes-Cruz A, Gutierrez-Suarez R, Pistorio A, Ravelli A, Loy A, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Walsh J, Penades IC, Alpigiani MG, Lahdenne P, Saad-Magalhaes C, Cortis E, Lepore L, Kimura Y, Wouters C, Martini A, Ruperto N: Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:309-314.
28. Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, Hafner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HI, Gamir ML, Magnusson B, Dressler F, Uziel Y, Van Rossum MA, Hollingworth P, Cawkwell G, Martini A, Ruperto N: Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis 2010, 69:1479-1483. 10.1136/ard.2009.120840
29. Wallace CA, Sherry DD, Mellins ED, Aiken RP: Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993, 20:118-122.
30. Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, ten Cate R, Guchelaar HJ: Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009, 61:46-51.
31. Yanagimachi M, Naruto T, Hara T, Kikuchi M, Hara R, Miyamae T, Imagawa T, Mori M, Kaneko T, Morita S, Goto H, Yokota S: Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br J Clin Pharmacol 2011, 71:237-243. 10.1111/j.1365-2125.2010.03814.x
32. Schmeling H, Biber D, Heins S, Horneff G: Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol 2005, 32:1832-1836.
33. Ravelli A, Ramenghi B, Di Fuccia G, Ruperto N, Zonta L, Martini A: Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. Acta Paediatr 1994, 83:428-432. 10.1111/j.1651-2227.1994.tb18135.x
34. Patil P, Rawcliffe C, Olaleye A, Moore S, Fox A, Sen D, Ioannou Y: Comparison of methotrexate induced nausea and vomiting between adolescent and adult patients with inflammatory arthritis. Rheumatology 2012, 51:iii107-iii108.
35. Steyerberg EW: Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York: Springer; 2009.
36. Malik F, Ranganathan P: Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics 2013, 14:305-314. 10.2217/pgs.12.214
37. Albertioni F, Flato B, Seideman P, Beck O, Vinje O, Peterson C, Eksborg S: Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995, 47:507-511.
38. Ruperto N, Ravelli A, Falcini F, Lepore L, De SR, Zulian F, Buoncompagni A, Sardella ML, Strano C, Alessio M, Viola S, Martini A: Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998, 57:38-41. 10.1136/ard.57.1.38
39. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A: Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009, 61:658-666. 10.1002/art.24516
40. Horneff G, Becker I: Definition of improvement in juvenile idiopathic arthritis using the Juvenile Arthritis Disease Activity Score. Rheumatology (Oxford) 2014, 53:1229-1234. 10.1093/rheumatology/ket470
41. Ringold S, Bittner R, Neogi T, Wallace CA, Singer NG: Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. Arthritis Care Res (Hoboken) 2010, 62:1095-1102. 10.1002/acr.20205